Links

Homepage

Stock List

Search by Ticker

News

Login

Zymeworks Inc. (NYSE:ZYME)
Stock Analysis

ZYME31.43
▲ 0.51%0.16

Stock Analysis

The following stock analysis is based on 3.3 years of data (i.e. since Apr 28, 2017). All the stock history has been downloaded.

Stock Exchange

Zymeworks Inc. trades on the NYSE exchange in USD dollars.

Sector

It is in the sector.

Current Status of Zymeworks Inc.

It is currently trading at $31.43 ($31.27 the previous day).

Financials

The next reporting date is in 95 days (2020 11 10).

The current Canada / US exchange rate is 1.33194.



Over the past 12 months, $367949 worth of shares have been purchased and $0 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is 30.9% per year assuming steady exponential growth. The actual 5 year average is 62.47. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year36.876458088235125.7+ Above Average
2 year16.33705645161343.8- Below Average
3 year11.36351464435117.9- Below Average
4 year9.64215189873420- Below Average
5 year0- Below Average
Zymeworks Inc. is projected by analysts to get to $54.00 within the next 12 months (71.8%), but preticted targets range from as high as $70.00 (122.7%) and as low as $42(33.6%).

Risk

The worst drop it has had in recent years is -51.5%. It has a shape to the stock curve, which means

Stock shape test

DAYS AG0PRICE
1031.7DROPPING
3035.98DROPPING
6036.6DROPPING
15038.12DROPPING
36523.35RISING
80020.27RISING
1200RISING
1600RISING
2000RISING
!!!!!!!!!!!! WARNING STOCK DROPPING !!!!!!!!!!!!!!!!!

With an average increase of 30.9% year over year, if Zymeworks Inc. is bought at the worst time, Stockmarketizer analysts estimate it will take 20 months before the stock will recover to the original purchase price.

Tradingview BuySell Widget

Yahoo News Feed

Is a Surprise Coming for Zymeworks (ZYME) This Earnings Season?

Thu, 06 Aug 2020 12:43:12 Zymeworks (ZYME) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.... Read Full Article

Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates

Thu, 06 Aug 2020 00:55:12 Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 26.74% and 44.72%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?... Read Full Article

Zymeworks Reports 2020 Second Quarter Financial Results

Wed, 05 Aug 2020 20:15:00 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the quarter ended June 30, 2020.... Read Full Article

Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Fri, 31 Jul 2020 16:30:04 Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.... Read Full Article

Did Hedge Funds Make The Right Call On Zymeworks Inc. (ZYME) ?

Sun, 12 Jul 2020 17:17:30 The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge ...... Read Full Article

Zymeworks Corporate Update Webcast and Conference Call Summary

Wed, 08 Jul 2020 21:30:00 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today hosted a webcast and conference call highlighting its progress and key accomplishments in the first half of 2020.... Read Full Article

Zymeworks Announces New Multispecific Antibody Collaboration with Merck

Wed, 08 Jul 2020 20:15:00 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longtime partner, Merck (known as MSD outside the US and Canada) have signed a new license agreement granting Merck the right to develop additional ...... Read Full Article

Zymeworks Announces Corporate Update Webcast and Conference Call

Tue, 30 Jun 2020 12:30:00 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that it will host a webcast and conference call to discuss progress on its corporate priorities and upcoming catalysts.... Read Full Article

Zymeworks (ZYME) Catches Eye: Stock Jumps 7.7%

Wed, 24 Jun 2020 12:41:12 Zymeworks (ZYME) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.... Read Full Article

Moving Average Crossover Alert: Zymeworks

Thu, 11 Jun 2020 13:03:01 Zymeworks Inc. (ZYME) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.... Read Full Article

Hedge Funds Can’t Buy Enough Of Zymeworks Inc. (ZYME)

Mon, 08 Jun 2020 20:13:15 In this article you are going to find out whether hedge funds think Zymeworks Inc. (NYSE:ZYME) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given ...... Read Full Article

Zymeworks to Present at the Jefferies 2020 Virtual Healthcare Conference

Thu, 28 May 2020 12:30:00 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Jefferies 2020 Virtual Healthcare Conference taking place June 2-4, 2020.... Read Full Article

Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

Fri, 08 May 2020 12:30:00 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 7, 2020 (the and"Meetingand").... Read Full Article

Zymeworks Reports 2020 First Quarter Financial Results

Thu, 07 May 2020 20:15:00 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2020.... Read Full Article

Hedge Funds Have Never Been This Bullish On Zymeworks Inc. (ZYME)

Wed, 15 Apr 2020 18:50:01 We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the SandP 500 Index was trading ...... Read Full Article

Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene

Wed, 01 Apr 2020 20:15:00 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in a two-arm Phase 1b/2 trial evaluating Zymeworks’ HER2-targeted bispecific antibody ZW25 in combination with chemotherapy ...... Read Full Article

Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors

Mon, 16 Mar 2020 10:50:00 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Kelvin Neu, M.D., to its Board of Directors.... Read Full Article

Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates

Mon, 02 Mar 2020 22:45:10 Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -97.62% and -79.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?... Read Full Article

Zymeworks Reports 2019 Year-End Financial Results

Mon, 02 Mar 2020 21:15:00 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2019.... Read Full Article
<